The relationship between systolic function and serum NGAL levels in patients with chronic heart failure of ischemic origin
Keywords:serum NGAL, left ventricular systolic function, chronic heart failure of ischemic origin, renal dysfunction, biomarker of tubulo-interstitial injury
Neutrophil gelatinase-associated lipocalin (NGAL) is considered one of the most informative biomarkers of chronic kidney disease (CKD). NGAL can also serve as a biomarker of cardiovascular disease and heart failure (HF). However, the relationship between systolic function and serum NGAL concentrations in patients with chronic HF (CHF) of ischemic origin remains insufficiently studied.
The aim. To study the influence of tubulo-interstitial injury marker NGAL on systolic function in patients with CHF of ischemic origin.
Materials and methods. The study included 51 patients with CHF, stage II AB, NYHA II-IV FC. Doppler echocardiographic examination was performed on the device Esaote MyLab Eight (Italy) according to standard methods. NGAL levels were analyzed using an ELISA kit (E-EL-H0096, Elabscience, USA). Depending to the concentration of serum NGAL, the patients were divided into 2 subgroups. In the first group (n = 37), the NGAL level was higher than 168 ng/ml, in the second (n = 14) – less than 168 ng/ml.
Results. The mean serum NGAL concentration in the first subgroup was 192 (183; 200) ng/ml, in the second subgroup – 154 (134; 160) ng/ml. The patients with CHF of ischemic origin with tubulo-interstitial injury (according to the serum concentration of NGAL) did not differ significantly from the patients with CHF of ischemic origin without tubulo-interstitial injury in age (P = 0.950), height (P = 0.983), weight (P = 0.681), body surface area (P = 0.975). Most of left ventricular systolic function indicators showed a downward tendency (S 6.90 ± 2.85 cm/s vs. 7.67 ± 2.83 cm/s (P = 0.536); S lat 7.33 ± 2.08 cm/s vs. 11.00 ± 4.00 cm/s (P = 0.467); TEI LV 0.56 ± 0.26 c.u. vs. 0.49 ± 0.14 c.u. (P = 0.747)) in the patients with CHF of ischemic origin with elevated serum levels of NGAL compared to similar indicators in the patients with CHF of ischemic origin without tubulo-interstitial injury. The index of LVEF was significantly lower in the patients with CHF with elevated serum NGAL compared to that in the patients with CHF with normal serum NGAL (50.43 ± 17.85 % vs. 63.29 ± 13.24 % (P = 0.021)).
Conclusions. Serum NGAL was not only the sensitive marker of tubulo-interstitial injury in patients with CHF of ischemic origin, but also appeared to be a predictor of changes in systolic heart function.
Damman, K., Masson, S., Hillege, H. L., Voors, A. A., van Veldhuisen, D. J., Rossignol, P., Proietti, G., Barbuzzi, S., Nicolosi, G. L., Tavazzi, L., Maggioni, A. P., & Latini, R. (2013). Tubular Damage and Worsening Renal Function in Chronic Heart Failure. JACC: Heart Failure, 1(5), 417-424. https://doi.org/10.1016/j.jchf.2013.05.007
Ronco, C., Legrand, M., Goldstein, S. L., Hur, M., Tran, N., Howell, E. C., Cantaluppi, V., Cruz, D. N., Damman, K., Bagshaw, S. M., Di Somma, S., & Lewington, A. (2014). Neutrophil Gelatinase-Associated Lipocalin: Ready for Routine Clinical Use? An International Perspective. Blood Purification, 37(4), 271-285. https://doi.org/10.1159/000360689
Kuzmin, O. B., Zhezha, V. V., Belaynin, V. V., Buchneva, N. V., Landar, L. N., & Serdyuk, S. V. (2017). Diagnosticheskaya i prognosticheskaya tsennost' biomarkerov povrezhdeniya pochechnykh kanal'tsev NGAL, KIM-1, L-FABP u patsientov s khronicheskoi bolezn'yu pochek [Diagnostic and prognostic value of renal tubular injury biomarkers NGAL, KIM-1, L-FABP in chronic kidney disease patients]. Nefrologiya, 21(2), 24-32. [in Russian].
Bolignano, D., Coppolino, G., Lacquaniti, A., & Buemi, M. (2010). From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. European Journal of Clinical Investigation, 40(3), 273-276. https://doi.org/10.1111/j.1365-2362.2010.02258.x
Oikonomou, E., Tsalamandris, S., Karlis, D., Siasos, G., Chrysohoou, C., Vogiatzi, G., Dimitropoulos, S., Charalambous, G., Kouskouni, E., & Tousoulis, D. (2018). The association among biomarkers of renal and heart function in patients with heart failure: the role of NGAL. Biomarkers in Medicine, 12(12), 1323-1330. https://doi.org/10.2217/bmm-2018-0100
van Deursen, V. M., Damman, K., Voors, A. A., van der Wal, M. H., Jaarsma, T., van Veldhuisen, D. J., & Hillege, H. L. (2014). Prognostic Value of Plasma Neutrophil Gelatinase–Associated Lipocalin for Mortality in Patients With Heart Failure. Circulation: Heart Failure, 7(1), 35-42. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000242
Voronkov, L. H., Amosova, K. M., Dziak, H. V., Zharinov, O. Y., Kovalenko, V. M., Korkushko, O. V., Nesukai, O. H., Sychov, O. S., Rudyk, Yu. S., & Parkhomenko, O. M. (2017). Rekomendatsii Asotsiatsii kardiolohiv Ukrainy z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti (2017) [Guidelines of the Ukrainian Association of Cardiology for the Diagnosis and Treatment of Chronic Heart Failure (2017)]. Sertseva nedostatnist ta komorbidni stany, (1, dodatok 1), 1-66. [in Ukranian].
WRITING COMMITTEE MEMBERS, Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Jr, Colvin, M. M., Drazner, M. H., Filippatos, G., Fonarow, G. C., Givertz, M. M., Hollenberg, S. M., Lindenfeld, J., Masoudi, F. A., McBride, P. E., Peterson, P. N., Stevenson, L. W., & Westlake, C. (2016). 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 134(13), e282-e293. https://doi.org/10.1161/CIR.0000000000000435
Poniatowski, B., Malyszko, J., Bachorzewska-Gajewska, H., Malyszko, J. S., & Dobrzycki, S. (2009). Serum Neutrophil Gelatinase-Associated Lipocalin as a Marker of Renal Function in Patients with Chronic Heart Failure and Coronary Artery Disease. Kidney and Blood Pressure Research, 32(2), 77-80. https://doi.org/10.1159/000208989
Maisel, A. S., Mueller, C., Fitzgerald, R., Brikhan, R., Hiestand, B. C., Iqbal, N., Clopton, P., & van Veldhuisen, D. J. (2011). Prognostic utility of plasma neutrophil gelatinase‐associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B‐type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. European Journal of Heart Failure, 13(8), 846-851. https://doi.org/10.1093/eurjhf/hfr087
Damman, K., van Veldhuisen, D. J., Navis, G., Voors, A. A., & Hillege, H. L. (2008). Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. European Journal of Heart Failure, 10(10), 997-1000. https://doi.org/10.1016/j.ejheart.2008.07.001
Alvelos, M., Pimentel, R., Pinho, E., Gomes, A., Lourenço, P., Teles, M. J., Almeida, P., Guimarães, J. T., & Bettencourt, P. (2011). Neutrophil Gelatinase-Associated Lipocalin in the Diagnosis of Type 1 Cardio-Renal Syndrome in the General Ward. Clinical Journal of the American Society of Nephrology, 6(3), 476-481. https://doi.org/10.2215/CJN.06140710
Macdonald, S., Arendts, G., Nagree, Y., & Xu, X. F. (2012). Neutrophil Gelatinase-Associated Lipocalin (NGAL) predicts renal injury in acute decompensated cardiac failure: a prospective observational study. BMC Cardiovascular Disorders, 12, Article 8. https://doi.org/10.1186/1471-2261-12-8
Mortara, A., Bonadies, M., Mazzetti, S., Fracchioni, I., Delfino, P., Chioffi, M., Bersano, C., & Specchia, G. (2013). Neutrophil gelatinase-associated lipocalin predicts worsening of renal function in acute heart failure: methodological and clinical issues. Journal of Cardiovascular Medicine, 14(9), 629-634. https://doi.org/10.2459/JCM.0b013e3283629ca6
Jungbauer, C. G., Birner, C., Jung, B., Buchner, S., Lubnow, M., von Bary, C., Endemann, D., Banas, B., Mack, M., Böger, C. A., Riegger, G., & Luchner, A. (2011). Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. European Journal of Heart Failure, 13(10), 1104-1110. https://doi.org/10.1093/eurjhf/hfr102
Shrestha, K., Shao, Z., Singh, D., Dupont, M., & Tang, W. H. (2012). Relation of Systemic and Urinary Neutrophil Gelatinase-Associated Lipocalin Levels to Different Aspects of Impaired Renal Function in Patients With Acute Decompensated Heart Failure. The American Journal of Cardiology, 110(9), 1329-1335. https://doi.org/10.1016/j.amjcard.2012.06.035
Siasos, G., Tousoulis, D., Michalea, S., Oikonomou, E., Vavuranakis, M., Athanasiou, D., Tourikis, P., Gouliopoulos, N., Miliou, A., Mourouzis, K., Limperi, M., Mazaris, S., Papavassiliou, A. G., & Stefanadis, C. (2014). Novel Biomarkers Assessing Renal Function in Heart Failure: Relation to Inflammatory Status and Cardiac Remodelling. Current Medicinal Chemistry, 21(34), 3976-3983. https://doi.org/10.2174/0929867321666140826114656
Martínez-Martínez, E., Buonafine, M., Boukhalfa, I., Ibarrola, J., Fernández-Celis, A., Kolkhof, P., Rossignol, P., Girerd, N., Mulder, P., López-Andrés, N., Ouvrard-Pascaud, A., & Jaisser, F. (2017). Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB Pathway. Hypertension, 70(6), 1148-1156. https://doi.org/10.1161/HYPERTENSIONAHA.117.09791
Yndestad, A., Landrø, L., Ueland, T., Dahl, C. P., Flo, T. H., Vinge, L. E., Espevik, T., Frøland, S. S., Husberg, C., Christensen, G., Dickstein, K., Kjekshus, J., Øie, E., Gullestad, L., & Aukrust, P. (2009). Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. European Heart Journal, 30(10), 1229-1236. https://doi.org/10.1093/eurheartj/ehp088
Sahinarslan, A., Kocaman, S. A., Bas, D., Akyel, A., Ercin, U., Zengin, O., & Timurkaynak, T. (2011). Plasma neutrophil gelatinase-associated lipocalin levels in acute myocardial infarction and stable coronary artery disease. Coronary Artery Disease, 22(5), 333-338. https://doi.org/10.1097/MCA.0b013e3283472a71
Shalenkova, M. A., Mikhailova, Z. D., & Klimkin, P. F. (2018). NGAL kak marker nekotorykh vyepochechyykh oslozhnenii pri ostrom koronarnom syndrome [NGAL as a marker for some extrarenal complications in acute coronary syndrome]. Kardiologiya, 58(S3), 19-26. [in Russian].
Vlachopoulos, C., Xaplanteris, P., Aboyans, V., Brodmann, M., Cífková, R., Cosentino, F., De Carlo, M., Gallino, A., Landmesser, U., Laurent, S., Lekakis, J., Mikhailidis, D. P., Naka, K. K., Protogerou, A. D., Rizzoni, D., Schmidt-Trucksäss, A., Van Bortel, L., Weber, T., Yamashina, A., Zimlichman, R., … Townsend, R. R. (2015). The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis, 241(2), 507-532. https://doi.org/10.1016/j.atherosclerosis.2015.05.007
How to Cite
LicenseAuthors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)